Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in ...

Developer Hadley Property Group has lodged a hybrid planning application to redevelop the flagship former GlaxoSmithKline ...

Hadley Property Group has submitted plans to transform GSK House, biopharma company GSK's former headquarters in west London, ...

Jazz Pharmaceuticals has struck a deal to bolster its epilepsy ambitions, paying Saniona $42.5 million upfront for a ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...

Dividend shares are one way of taking the battle to rising inflation. Our writer picks out three FTSE 100 stocks that might ...

The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

GSK PLC closed 14.28% short of its 52-week high of £16.79, which the company reached on September 9th.

In late April, the FDA notified SCYNEXIS that the clinical hold on ibrexafungerp had been lifted and concluded that the Phase 3 MARIO study could resume. The MARIO study is a Phase 3 trial evaluating ...

Spero Therapeutics, Inc. (NASDAQ: SPRO) Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats ...